A Study of Tislelizumab (BGB-A317) in Combination With Chemotherapy as First Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma
BeiGene
BeiGene
BeiGene
BeiGene
Ludwig Institute for Cancer Research
Peking Union Medical College Hospital
Fudan University
Innovent Biologics (Suzhou) Co. Ltd.
Sun Yat-sen University
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Radiation Therapy Oncology Group
Fudan University
Innovent Biologics (Suzhou) Co. Ltd.
Novartis
Fudan University
Radiation Therapy Oncology Group
Alliance for Clinical Trials in Oncology
Fox Chase Cancer Center
Radiation Therapy Oncology Group
Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)
UNC Lineberger Comprehensive Cancer Center
Weill Medical College of Cornell University